Various cancer cell signaling pathways that promote cancer development, such as receptor tyrosine kinases (RTKs), MAPK, PI3K-AKT-mTOR, and JAK-STAT, play a role in making immune checkpoint therapy less effective. This evidence concerns the gene AKT1 and cancer.